[ad_1]
GSK’s presence in immunology and irritation is closely oriented round respiratory medicine, however the firm been increasing its scope by way of enterprise offers. The pharmaceutical large is now including meals allergy by way of the $2.2 billion acquisition of Rapt Therapeutics, a biotech whose lead program provides potential dosing and efficacy benefits over a blockbuster product marketed by two of GSK’s massive pharma friends.
Based on monetary phrases introduced Tuesday, GSK pays $58 in money for every share of Rapt, which represents a 65.2% premium to the inventory’s closing value on Friday. When South San Francisco-based Rapt went public in 2019, it priced its shares at $12 every.
Rapt drug ozureprubart is a monoclonal antibody designed to inhibit immunoglobulin E (IgE), a sort of antibody that the physique produces in excessive quantities in response to an allergen. An anti-IgE-antibody drug is already out there to these with meals allergy symptoms, the every-two-to-four weeks injectable remedy omalizumab. This drug was first accepted in 2003 for treating moderate-to-severe bronchial asthma. The 2024 FDA approval of the antibody for meals allergy is the most recent in an extended line of immunological indications for the blockbuster product, marketed by companions Genentech, a Roche subsidiary, and Novartis beneath the model identify Xolair. Roche, which data U.S. gross sales of the drug, reported 2.4 billion Swiss francs (about $3.1 billion) in Xolair income throughout all of its accepted indications.
Rapt’s ozureprubart, previously generally known as RPT904, was developed by making focused modifications to the omalizumab sequence, extending its half-life and bettering its drug-like properties. This long-acting antibody provides the potential for dosing each 12 weeks for prophylactic safety towards meals allergens. A Part 2b take a look at of ozureprubart as a monotherapy is underway with a focused enrollment of 100 members age 12 to 55 with a confirmed meals allergy. The placebo-controlled examine is testing dosing each eight or 12 weeks; information are anticipated subsequent yr.
In a observe despatched to traders, Leerink Companions analyst Thomas Smith wrote that the Rapt drug has proven best-in-class potential in IgE-mediated ailments. That features meals allergy, an enormous business alternative of about 17 million identified sufferers within the U.S. that gives loads of room for brand spanking new choices bringing higher efficacy and fewer frequent dosing, he mentioned. Smith added that the Rapt drug might supply the flexibility to deal with sufferers with elevated baseline IgE ranges who’re ineligible for Xolair. Leerink sees no indication-specific overlap with GSK’s immunology pipeline, reducing the regulatory threat to closing the acquisition.
“Total, we consider the RAPT acquisition is a robust strategic match for GSK, who can leverage their respiratory, immunology, and irritation (RI&I) experience, mixed with their broad business infrastructure, to unlock a possible multi-blockbuster alternative for ozureprubart in meals allergy and different IgE-mediated indications,” Smith wrote. “We consider this deal was doubtless a aggressive course of with a number of bidders, however can’t rule out the potential for competing bids shifting ahead.”
GSK mentioned the Rapt drug builds on its expertise and experience in irritation and immunology whereas additionally aligning with the present relationships the corporate has with allergists who prescribe its respiratory medicine. The GSK immunology pipeline has been rising. Final yr, GSK paid $1.2 billion to accumulate Boston Prescription drugs’ efimosfermin, a drug in growth to deal with the irritation and fibrosis brought on by the fatty liver illness generally known as MASH. 2025 enterprise offers additionally introduced GSK power obstructive pulmonary illness drug candidates from startup Empirico and Hengrui Pharma. In a ready assertion, GSK Chief Scientific Officer Tony Wooden mentioned ozureprubart provides best-in-class potential for meals allergy.
“Meals allergy symptoms trigger extreme well being impacts to sufferers with present remedy requiring injections as steadily as each two weeks,” he mentioned. “Ozureprubart provides the chance to convey sustained safety to sufferers with dosing each 12 weeks, and is per our method to accumulate property that deal with validated targets and the place there’s clear unmet medical want.”
Rapt licensed ozureprubart from a China-based biotech now generally known as Shanghai Jeyou Pharmaceutical Co. That 2024 deal gave Rapt a brand new lead program after the corporate discontinued zelnecirnon, an experimental remedy for bronchial asthma and atopic dermatitis. In early 2024, the FDA positioned assessments of the oral small molecule beneath a medical maintain after a report of liver failure.
The ozureprubart deal granted Rapt world rights to the drug, excluding mainland China, Hong Kong, Macau, and Taiwan, the place Jeyou retains rights. Rapt paid $35 million up entrance and will pay an extra $672.5 million in milestone funds, in response to the corporate’s regulatory filings. Jeyou may even obtain royalty funds on web gross sales of ozureprubart if it reaches the market. Per the acquisition settlement, GSK assumes accountability for these funds. The Rapt pipeline additionally contains the most cancers drug tivumecirnon, an oral small molecule CCR4 antagonist designed to maintain immunosuppressive regulatory T cells from migrating into tumors. In regulatory filings, Rapt mentioned it has been searching for a associate to develop this drug.
Whereas the Rapt acquisition values the biotech at about $2.2 billion, GSK estimates its fee, minus the money Rapt has in its accounts, will probably be about $1.9 billion. The acquisition settlement requires nearly all of Rapt shareholders to tender their shares. GSK expects to finish the transaction within the present quarter.
Picture by GSK
[ad_2]
